Lessons Learned and Questions Raised by an Atypical Case of Clozapine-Induced Myocarditis

Area of Science:

• Cardiology
• Psychiatry
• Pharmacology

Background:

• Clozapine is an effective antipsychotic for treatment-resistant schizophrenia.
• Clozapine induction can cause side effects, including tachycardia and, rarely, myocarditis.
• Myocarditis poses significant mortality risks and diagnostic challenges.

Purpose of the Study:

• To report a case of clozapine-induced myocarditis in a young adult with treatment-resistant schizophrenia.
• To discuss the diagnostic difficulties and clinical presentation of this adverse event.
• To raise awareness regarding the potential need for systematic screening for myocarditis during clozapine initiation.

Main Methods:

• A case report of a patient treated with clozapine.
• Clinical observation including vital signs, ECG, and blood tests.
• Cardiac enzyme level assessment and echocardiogram for diagnosis.
• Withdrawal of clozapine and initiation of cardiac management.

Main Results:

• The patient developed persistent tachycardia and an episode of collapse after starting clozapine.
• Elevated cardiac enzymes and echocardiogram findings confirmed myocarditis.
• The patient recovered successfully after clozapine withdrawal and cardiac treatment.

Conclusions:

• Clozapine-induced myocarditis is a critical adverse event requiring prompt recognition and management.
• The case underscores the diagnostic challenges and potential severity of this condition.
• Consideration should be given to implementing formal screening protocols for myocarditis in patients initiating clozapine therapy.